Shandong Provincial Hospital   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Jinan China (1897)

Organization Overview

First Clinical Trial
2009
NCT01506414
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Qinghua Xia,Prof | Shandong Proincial Hospital | Shandong Province Hospital | Shandong Provincial Hospital

Active Ingredients

Drugs in Phase 4 Trials (46)

Azvudine (1 trial)

bortezomib (velcade) (1 trial)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (7 trials)

dapsone (aczone) (1 trial)

dexamethasone (2 trials)

dexmedetomidine (precedex) (1 trial)

doxorubicin (Doxil) (7 trials)

epirubicin (ellence) (4 trials)

etoposide (vepesid) (4 trials)

Filgrastim (neupogen) (2 trials)

furazolidone (furoxone) (1 trial)

gemcitabine (gemzar) (2 trials)

heparin (liquaemin) (1 trial)

ifosfamide (ifex) (1 trial)

ilaprazole (noltec) (1 trial)

lenalidomide (revlimid) (3 trials)

levofloxacin (levaquin) (1 trial)

levothyroxine (Synthroid) (2 trials)

metronidazole (flagyl) (1 trial)

micafungin (mycamine) (1 trial)

midazolam (versed) (1 trial)

naltrexone (revia) (1 trial)

nirmatrelvir (Paxlovid) (1 trial)

octreotide (sandostatin) (1 trial)

piperacillin (pipracil) (1 trial)

prednisone (meticorten) (7 trials)

procaine benzylpenicillin (novocaine) (1 trial)

propofol (diprivan) (1 trial)

qiliqiangxin (1 trial)

ritonavir (Norvir) (1 trial)

rituximab (rituxan) (8 trials)

sargramostim (leukine) (2 trials)

saxagliptin (onglyza) (1 trial)

sitagliptin (januvia) (1 trial)

somatropin (protropin) (1 trial)

tazobactam (Zosyn) (1 trial)

tegafur (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

terlipressin (Terlivaz) (1 trial)

tetracycline (tetrex) (1 trial)

tinidazole (tindamax) (1 trial)

urea (5 trials)

vincristine (oncovin) (7 trials)

warfarin (coumadin) (1 trial)

yangxinshi (1 trial)

Drugs in Phase 3 Trials (20)

aclarubicin (1 trial)

alteplase (Activase) (2 trials)

azacitidine (vidaza) (2 trials)

caffeic acid (1 trial)

camrelizumab (2 trials)

capecitabine (xeloda) (3 trials)

cisplatin (platinol) (3 trials)

cytarabine (cytosar-u) (2 trials)

decitabine (dacogen) (3 trials)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

methotrexate (1 trial)

omacetaxine (synribo) (1 trial)

orelabrutinib (1 trial)

platelets (1 trial)

semaglutide (Ozempic) (1 trial)

somatostatin (1 trial)

thrombopoietin (6 trials)

tyroserleutide (1 trial)

zanubrutinib (Brukinsa) (2 trials)

Drugs in Phase 2 Trials (6)

almonertinib (1 trial)

chidamide (1 trial)

docetaxel (taxotere) (2 trials)

Nelonemdaz (1 trial)

Telitacicept (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 1 Trials (1)

acetylcysteine (mucomyst) (1 trial)

Drugs in Other Trials (13)

atropine (1 trial)

autologous mononuclear stem cell (1 trial)

bifidobacteria (1 trial)

cefotiam (ceradon) (1 trial)

crizotinib (xalkori) (1 trial)

duloxetine (Cymbalta) (1 trial)

erlotinib (tarceva) (1 trial)

gefitinib (iressa) (1 trial)

l-glutamine (1 trial)

rifaximin (xifaxan) (1 trial)

simethicone (IMODIUM) (1 trial)

sodium gualenate (1 trial)

weifuchun (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 4)

Atherosclerosis (Phase 4)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Transitional Cell (Phase 3)

Cardiomyopathies (Phase 4)

Cardiomyopathy, Dilated (Phase 4)

Cerebral Infarction (Phase 2)

Delirium (Phase 4)

Diabetes Mellitus (Phase 4)

Disease Susceptibility (Phase 4)

Endocrine System Diseases (Phase 4)

Enteropathy-Associated T-Cell Lymphoma (Phase 4)

Esophageal and Gastric Varices (Phase 4)

Gallbladder Neoplasms (Phase 3)

Glucose Intolerance (Phase 4)

Hematologic Neoplasms (Phase 4)

Hepatoblastoma (Phase 4)

Hodgkin Disease (Phase 4)

Hypersensitivity (Phase 4)

Hypothyroidism (Phase 4)

Immunoblastic Lymphadenopathy (Phase 4)

Infarction (Phase 2)

Leprosy (Phase 4)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Leukemia, T-Cell (Phase 3)

Lymphoma (Phase 4)

Lymphoma, B-Cell (Phase 4)

Lymphoma, Large-Cell, Anaplastic (Phase 4)

Lymphoma, Non-Hodgkin (Phase 4)

Lymphoma, T-Cell (Phase 4)

Lymphoma, T-Cell, Peripheral (Phase 4)

Multiple Myeloma (Phase 4)

Myelodysplastic Syndromes (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 4)

Neuroblastoma (Phase 4)

Neutropenia (Phase 4)

Obesity (Phase 4)

Panniculitis (Phase 4)

Pneumonia, Pneumocystis (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Prediabetic State (Phase 4)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Retinoblastoma (Phase 4)

Skin Diseases (Phase 4)

Skin Diseases, Vesiculobullous (Phase 4)

Stomach Neoplasms (Phase 2)

Stroke (Phase 2)

Thrombocytopenia (Phase 3)

Thyroid Diseases (Phase 4)

Urticaria (Phase 4)

Vasculitis (Phase 4)

Vasculitis, Leukocytoclastic, Cutaneous (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 60
  • # of Trial APIs: 86